Deborah Baker, NP
Family · Bluffton, INNPI 1467630061
Payments from drug & device makers
Across 527 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$909
- AbbVie$826
- Lundbeck LLC$697
- Tris Pharma Inc$687
- Otsuka America Pharmaceutical, Inc.$651
- plus $4K from 19 others
What the payments were for
- Food & beverage$8,16695%
- Education$4275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 52 | $1,056 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $909 |
| AbbVie | 69 | $826 |
| Lundbeck LLC | 50 | $697 |
| Tris Pharma Inc | 35 | $687 |
| Otsuka America Pharmaceutical, Inc. | 35 | $651 |
| Corium, LLC | 42 | $584 |
| Sunovion Pharmaceuticals Inc. | 29 | $550 |
| Alkermes, Inc. | 26 | $490 |
| Supernus Pharmaceuticals, Inc. | 29 | $409 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $309 |
| E.r. Squibb & Sons, L.L.C. | 22 | $288 |
| Axsome Therapeutics, Inc. | 11 | $189 |
| Neurocrine Biosciences, Inc. | 9 | $157 |
| Vanda Pharmaceuticals Inc. | 14 | $156 |
| Merck | 8 | $112 |
| Biogen | 4 | $98 |
| Eisai Inc. | 6 | $92 |
| Johnson & Johnson | 4 | $85 |
| Ironshore Pharmaceuticals Inc. | 3 | $70 |
| Noven Therapeutics, LLC | 4 | $70 |
| OWP Pharmaceuticals, Inc. | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$132
How this compares
$8,593 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 56 | $646,652 |
| AustedoDeutetrabenazine | 65 | $628,624 |
| RexultiBrexpiprazole | 188 | $306,076 |
| VraylarCariprazine Hcl | 168 | $254,912 |
| IngrezzaValbenazine Tosylate | 14 | $109,427 |
| TrintellixVortioxetine Hydrobromide | 95 | $78,301 |
| CaplytaLumateperone Tosylate | 43 | $74,408 |
| AuvelityDextromethorphan Hbr/Bupropion | 53 | $65,955 |
| AristadaAripiprazole Lauroxil | 19 | $60,525 |
| BelsomraSuvorexant | 129 | $60,316 |
| FanaptIloperidone | 13 | $56,440 |
| Abilify MaintenaAripiprazole | 14 | $31,240 |
| DayvigoLemborexant | 83 | $30,792 |
| Lurasidone Hcl | 42 | $22,309 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 190 | $19,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,056 | $1,275,276121 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $651 | $337,316202 claims |
| AbbVieVraylar | $826 | $254,912168 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $157 | $109,42714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $309 | $96,871142 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $909 | $74,40843 claims |
| Axsome Therapeutics, Inc.Auvelity | $189 | $65,95553 claims |
| Alkermes, Inc.Aristada | $490 | $60,52519 claims |
| MerckBelsomra | $112 | $60,316129 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $156 | $56,44013 claims |
| Eisai Inc.Dayvigo | $92 | $30,79283 claims |
| Tris Pharma IncDyanavel Xr | $687 | $5,53711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Bluffton
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.